TRPML3‑mediated lysosomal Ca 2+ release enhances drug sequestration and biogenesis, promoting osimertinib resistance in non‑small cell lung cancer
Oncology Reports · 2025
DOI: 10.3892/or.2025.8946 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Reports, 2025. Verfasst von Mi Seong Kim und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral Physiology, Institute of Biomaterial‑Implant, School of Dentistry, Wonkwang University, Iksan, Jeonbuk 54538, Republic of Korea. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Aniline Compounds, Drug Resistance, Neoplasm, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Lysosomes and lysosomal Ca2+ play crucial roles in cellular homeostasis and drug resistance. The lysosomal Ca2+ channel transient receptor potential mucolipin 3 (TRPML3; also known as mucolipin‑3 or MCOLN3) is a key regulator of autophagy and membrane trafficking; however, its role in tyrosine kinase inhibitor (TKI) resistance remains unclear. The contribution of TRPML3 to osimertinib resistance in non‑small cell lung cancer (NSCLC) was therefore assessed. Using publicly available RNA sequencing data, including profiles from clinical samples before and after osimertinib treatment, TRPML3 expression was measured in lung adenocarcinoma (LUAD) tissues. Additionally, two‑dimensional cell culture of, and three‑dimensional spheroids derived from, NSCLC cell lines were used to elucidate roles of TRPML3 in drug resistance. TRPML3 expression was significantly upregulated in both LUAD tissues from patients with residual disease after osimertinib treatment, as well as in osimertinib‑resistant NSCLC cells. TRPML3 knockdown in resistant PC9 cells restored sensitivity to osimertinib and multiple TKIs; this was replicated in spheroid models. Mechanistically, osimertinib induced intracellular Ca2+ oscillations in PC9 cells via lysosomal Ca2+ release through TRPML3 rather than through TRPML1. In summary, the present findings suggest that elevated TRPML3 expression compensates for TRPML1 to maintain lysosomal acidity and biogenesis during TKI treatment, facilitating drug sequestration and resistance and identifying TRPML3 as a potential target for overcoming osimertinib resistance in NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral Physiology, Institute of Biomaterial‑Implant, School of Dentistry, Wonkwang University, Iksan, Jeonbuk 54538, Republic of Korea.
Zitieren
APA
Kim, M. S., & Kim, M. S. (2025). TRPML3‑mediated lysosomal Ca 2+ release enhances drug sequestration and biogenesis, promoting osimertinib resistance in non‑small cell lung cancer. Oncology Reports. https://doi.org/10.3892/or.2025.8946
Vancouver
Kim MS, Kim MS. TRPML3‑mediated lysosomal Ca 2+ release enhances drug sequestration and biogenesis, promoting osimertinib resistance in non‑small cell lung cancer. Oncology Reports. 2025. doi:10.3892/or.2025.8946
BibTeX
@article{Kim2025,
author = {Kim, Mi Seong and Kim, Min Seuk},
title = {TRPML3‑mediated lysosomal Ca 2+ release enhances drug sequestration and biogenesis, promoting osimertinib resistance in non‑small cell lung cancer},
journal = {Oncology Reports},
year = {2025},
doi = {10.3892/or.2025.8946}
}
EUVIMED